Written information plans for patients receiving immunotherapydoi:10.1016/S1081-1206(10)61508-6Jean BousquetAnnals of Allergy, Asthma & Immunology
Today you have another first-line treatment option. Allergychoices can help your practice integrate custom, patient-specific sublingual immunotherapy using theLa Crosse Method™ Protocol. In use since 1970, the Protocol is uniquely optimized to your patients’ needs, with treatment targeting their spe...
Informing Patients With Cancer About the Potential Impact of Immunotherapy on Pregnancy Diagnosis of cancer during pregnancy, as well as pregnancy arising during cancer treatment, is not common. Oncology nurses have good knowledge of teratogenic effects of chemotherapy and the potential...
Investigators from Dana-Farber Cancer Institute, Yale Cancer Center, AdventHealth and other centers retrospectively looked at a multi-institutional, international cohort of 92 patients with advancedpenile cancerto assess the efficacy of ICIs. The most common ICIs given were pembrolizumab, nivolumab, and ...
sufficient.Therefore,we interpret the relevant research results of these 7 groups of people in order to put forward inference and suggestions for the clinical optimization when using of immune checkpoint inhibitors,to provide a reference for medical staffs and to bring more benefits to the patients....
Joseph Obeid and Craig Slingluff Jr. would like to thank the National Cancer Institute for the funding provided for salary support NCI T32 CA163177 and NCI P30 CA044579, respectively. Author information Authors and Affiliations Department of Surgery, University of Virginia, Charlottesville, VA, USA...
Despite the significant therapeutic progress in immunotherapy, many challenges persist: the biomarkers with definite cut-off values remain unknown; the majority of patients with GI tract cancers still suffer from primary or secondary resistance; the strategies for patients with specific subtypes have not...
We aim to create an immunotherapy-related signature that can play a role in predicting HCC patients’ survival and therapeutic outcomes. Immunotherapy-related genes were discovered first. Clinical information and gene expression data were extracted from GSE140901. By a series of bioinformatics methods ...
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated with 2 doses (in weeks 1 and
Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol. 2023;9(10):1348-1355. doi:10.1001/jamaoncol.2023.2751 ...